Amicus Therapeutics
FOLD
FOLD was delisted on the 24th of April, 2026.
195 hedge funds and large institutions have $2.21B invested in Amicus Therapeutics in 2018 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 68 increasing their positions, 62 reducing their positions, and 33 closing their positions.
319% more call options, than puts
Call options by funds: $11.4M | Put options by funds: $2.72M
1.4% more ownership
Funds ownership: 102.07% → 103.47% (+1.4%)
10% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 62
4% less funds holding
Funds holding: 204 → 195 (-9)
20% less capital invested
Capital invested by funds: $2.76B → $2.21B (-$550M)
24% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 33
33% less funds holding in top 10
Funds holding in top 10: 9 → 6 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$49.2M |
| 2 |
Janus Henderson Group
London,
|
+$24.9M |
| 3 |
MWNA
Marshall Wace North America
New York
|
+$24.7M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$16.2M |
| 5 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$11.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$18M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$17.8M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$17.4M |
| 4 |
TCP
Tourbillon Capital Partners
New York
|
-$17.1M |
| 5 |
D.E. Shaw & Co
New York
|
-$16.6M |
FOLD Hedge Fund Activity: Q4 2018 in Review
195 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q4 2018, worth a combined $2.21B — down 20% from $2.76B a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of FOLD and 25 opened new positions — a net loss of 8 holders — while 62 trimmed existing stakes and 68 added.
The largest buyer was Fidelity Investments, adding an estimated $49.2M. The largest seller was Ameriprise, cutting an estimated $18M.
- 195 institutional investors held Amicus Therapeutics (FOLD) as of Q4 2018, down from 204 in Q3 2018.
- Funds reported $2.21B of Amicus Therapeutics stock for Q4 2018, down 20% quarter-over-quarter.
- 25 funds opened new Amicus Therapeutics positions in Q4 2018 and 33 closed out, a net change of -8 holders.
- The largest Amicus Therapeutics buyer in Q4 2018 was Fidelity Investments, an estimated $49.2M added.
- The largest Amicus Therapeutics seller in Q4 2018 was Ameriprise, an estimated $18M sold.
Based on aggregated 13F filings for Q4 2018.